Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

s of our business, sales, earnings and cash flow in light of current general economic conditions; sales, SG&A, R&D, adjusted net income and basic adjusted income per common share guidance for full-year 2008 and full- year 2009; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Adjusted Net Income Guidance," "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.

CEPHALON, INC. AND SUBSIDIARIES

CONSO
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... Bruno, CA. (PRWEB) , ... July 29, 2015 ... ... agreement with PRC Clinical, a Silicon Valley-based CRO specializing in Clinical ... advisory services, and patient recruitment services. The core expertise of PRC Clinical is ...
(Date:7/29/2015)... Littleton, MA (PRWEB) , ... July 29, 2015 , ... ... range of serious diseases. Yet few people realize that a rich source of these ... or young adults, and teeth that need to be pulled to make room for ...
(Date:7/28/2015)... -- People with a common form of hearing loss ... profound improvements in their hearing and understanding of speech ... multicenter study led by specialists at NYU Langone Medical ... of print in the journal The Laryngoscope July 7, researchers ... the United States implanted hybrid cochlear ...
Breaking Biology Technology:Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Toothâ„¢ Dental Stem Cell Banking Available to their Patients 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... Milwaukee Merge eFilm will acquire ... software line in a $6 million cash deal announced ... Merge Technologies Incorporated, expects to close the deal with ... software, used by radiologists and other specialty physicians, includes ...
... are into the home stretch of the year with just December ... market, there are in reality about two weeks left in the ... (as far as IPOs go) by the middle of December. New ... ,What seemed like a promising and valiant biotech IPO market has ...
... in talks with Australian banks , Brookfield, Wis. ... three major Australian banks Commonwealth Bank of Australia, National ... Vipro check processing system. If negotiations are completed successfully, the ... all processing operations managed by Fiserv. , Herrera to join ...
Cached Biology Technology:Midwest life-science company Perrigo globalizes under the radar 2Midwest life-science company Perrigo globalizes under the radar 3Midwest life-science company Perrigo globalizes under the radar 4Midwest life-science company Perrigo globalizes under the radar 5
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... health and wellbeing, say researchers in this week's BMJ. ... contact with nature. , Use of wildlife in some ... the authors. Smaller animals (for example, squirrels, owls, and ... with emotional and behavioural problems. , People who take ...
... do not receive adequate amounts of zinc from their ... HIV-infected, according to researchers from the Johns Hopkins Bloomberg ... it was not known if zinc would speed up ... load. Zinc supplementation is known to decrease the frequency ...
... 20 years later a UN report provides definitive answers and ... four thousand people could eventually die of radiation exposure from ... ago, an international team of more than 100 scientists has ... had been directly attributed to radiation from the disaster, almost ...
Cached Biology News:Zinc supplements safe for HIV-infected children 2Chernobyl: The true scale of the accident 2Chernobyl: The true scale of the accident 3Chernobyl: The true scale of the accident 4Chernobyl: The true scale of the accident 5Chernobyl: The true scale of the accident 6Chernobyl: The true scale of the accident 7Chernobyl: The true scale of the accident 8Chernobyl: The true scale of the accident 9Chernobyl: The true scale of the accident 10Chernobyl: The true scale of the accident 11Chernobyl: The true scale of the accident 12Chernobyl: The true scale of the accident 13Chernobyl: The true scale of the accident 14Chernobyl: The true scale of the accident 15Chernobyl: The true scale of the accident 16
... , Coated Capture Antibody: 12 x 8-well strips, ... mL of 2X concentrate , Beta Amyloid ... , Lyophilized Standard Diluent: 3 mL , Primary ... Antibody-HRP: 30 microL of concentrate , OPD Substrate: ...
Human Cell Line Slides...
Request Info...
HSV 1 IgM...
Biology Products: